Feminine Cleanser Marketing Never Without Challenges; Now The Category Has FDA’s Attention
This article was originally published in The Rose Sheet
Executive Summary
FDA is investigating use of certain ingredients in feminine cleansing and hygiene products, according to its fiscal 2019 budget justification. The agency’s work could draw unfavorable attention to a category that already comes under fire regularly for alleged body shaming and disproportionate ill effects on women of color, among other accusations.
You may also be interested in...
CIR On MoCRA Product Listing: FDA Should Refine Categories For Optimal Data Collection
Cosmetic product/ingredient listing required by new cosmetics regulations will be a boon for CIR, which has conducted its ingredient reviews to date based on limited, voluntary data reporting. Adding new product classifications and subcategories to the US FDA’s listing system could provide needed insight into dry shampoo and other product formats and help identify potential for incidental inhalation risks.
Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop
While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.
Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop
While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.